GBP1 and neoplasm: Knocking down GBP1 restores erlotinib sensitivity in lung cancer, shrinking tumors and prolonging G1 phase arrest, trackable via cell cycle analysis, positron emission tomography (PET) imaging, or tumor biopsies, offering a dynamic response marker [68].